en

PRODUCT DETAIL

Lazcluze 240 mg filmom obalené tablety

Code 8876E
MA number EU/1/24/1886/006
Product Form: tbl flm 30x240 mg (fľ.HDPE)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
MAH, country: Janssen - Cilag International N.V., Belgium
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E Protein kinase inhibitors
L01EB Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
L01EB09 Lazertinib
Shelf life: 24
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 20.01.2025
Validity: 20.01.2030
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 30.01.2025
eu-flag.png sk-flag.png